@article{1f4b10a274324a56a9b7ade7d608ded8,
title = "The Concise Health Risk Tracking-Self Report: Psychometrics within a placebo-controlled antidepressant trial among depressed outpatients",
abstract = " Background/aims: While substantial prior research has evaluated the psychometric properties of the 12-item Concise Health Risk Tracking-Self Report (CHRT-SR 12 ), a measure of suicide propensity and suicidal thoughts, no prior research has investigated its factor structure, sensitivity to change over time, and other psychometric properties in a placebo-controlled trial of antidepressant medication, nor determined whether symptoms change throughout treatment. Methods: Participants in the multi-site Establishing Moderators and Biosignatures of Antidepressant Response in Clinical Care (EMBARC) study (n=278) provided data to evaluate the factor structure and sensitivity to change over time of the CHRT-SR 12 through eight weeks of a clinical trial in which participants received either placebo or antidepressant medication (sertraline). Results/Outcomes: Factor analysis confirmed two factors: propensity (comprised of first-order factors including pessimism, helplessness, social support, and despair) and suicidal thoughts. Internal consistency (α{\textquoteright}s ranged from 0.69–0.92) and external validity were both acceptable, with the total score and propensity factor scores significantly correlated with total scores and single-item suicidal-thoughts scores on the self-report Quick Inventory of Depressive Symptoms and the clinician-rated 17-item Hamilton Rating Scale for Depression. Through analyzing CHRT-SR 12 changes over eight treatment weeks, the total score and both the factors decreased regardless of baseline suicidal thoughts. Change in clinician-rated suicidal thoughts was reflected by change in both the total score and propensity factor score. Conclusions/interpretation: These results confirm the reliability, validity, and applicability of the CHRT-SR 12 to a placebo-controlled clinical trial of depressed outpatients receiving antidepressant medication. ",
keywords = "Concise Health Risk Tracking-Self Report, major depression, psychometrics, suicidal thoughts, suicide ratings",
author = "Trombello, {Joseph M.} and Killian, {Michael O.} and Grannemann, {Bruce D.} and Rush, {Augustus John} and Mayes, {Taryn L.} and Parsey, {Ramin V.} and Melvin McInnis and Jha, {Manish K.} and Aasia Ali and McGrath, {Patrick J.} and Phil Adams and Oquendo, {Maria A.} and Weissman, {Myrna M.} and Carmody, {Thomas J.} and Trivedi, {Madhukar H.}",
note = "Funding Information: The author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: J Trombello currently owns stock in Merck and Gilead Sciences and within the past 36 months previously owned stock in Johnson and Johnson. A Rush has received consulting fees from Akili, Brain Resource Inc., Compass Inc., Curbstone Consultant LLC, Emmes Corp, Holmusk, Inc., Liva-Nova, Sunovion, Takeda USA, Taj Medical; speaking fees from Liva-Nova; royalties from Guilford Press and the University of Texas Southwestern Medical Center, Dallas, Texas (for the Inventory of Depressive Symptoms and its derivatives). He is also named co-inventor on two patents: US Patent No. 7,795,033: Methods to Predict the Outcome of Treatment with Antidepressant Medication, Inventors: McMahon FJ, Laje G, Manji H, Rush AJ, Paddock S, Wilson AS and US Patent No. 7,906,283: Methods to Identify Patients at Risk of Developing Adverse Events During Treatment with Antidepressant Medication, Inventors: McMahon FJ, Laje G, Manji H, Rush AJ, Paddock S. P McGrath has received funding from the National Institute of Mental Health, New York State Department of Mental Hygiene, Research Foundation for Mental Hygiene (New York State), Forest Research Laboratories, Sunovion Pharmaceuticals, and Naurex Pharmaceuticals (now Allergan). M Oquendo receives royalties for the commercial use of the Columbia Suicide Severity Rating Scale. Her family owns stock in Bristol Myers Squibb. M Weissman has received funding from the National Institute of Mental Health (NIMH), the National Institute on Drug Abuse (NIDA), the National Alliance for Research on Schizophrenia and Depression (NARSAD), the Sackler Foundation, the Templeton Foundation; and receives royalties from the Oxford University Press, Perseus Press, the American Psychiatric Association Press, and MultiHealth Systems. T Carmody has received an honorarium from UT San Antonio. M Trivedi has received consulting fees from or has served on the advisory boards of Alkeremes Inc., Akili Interactive, Navitor, and Otsuka America Pharmaceutical Inc.; holds author agreements with Janssen Asia Pacific and Oxford University Press; honoraria from the American Psychiatric Association; and grants from the Cancer Prevention and Research Institute of Texas (CPRIT), NIMH, NIDA, National Center for Advancing Translational Sciences (NCATS), Johnson and Johnson, PCORI. P Adams, T Mayes, R Parsey, M McInnis, M Jha, A Ali, M Killian, and B Grannemann have no conflicts to report. All authors have approved this manuscript. Funding Information: The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: The EMBARC study was supported by the National Institute of Mental Health of the National Institutes of Health under award numbers U01MH092221 (MH Trivedi) and U01MH092250 (PJ McGrath, RV Parsey, MM Weissman). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. Valeant Pharmaceuticals donated the Wellbutrin XL used in the study. This work was supported by the EMBARC National Coordinating Center at UT Southwestern Medical Center, MH Trivedi, Coordinating PI, and the Data Center at Columbia and Stony Brook Universities. Clinical trials: Establishing Moderators and Biosignatures of Antidepressant Response for Clinical Care for Depression (EMBARC), https://clinicaltrials.gov/ ct2/show/NCT01407094.",
year = "2019",
month = feb,
day = "1",
doi = "10.1177/0269881118817156",
language = "English (US)",
volume = "33",
pages = "185--193",
journal = "Journal of Psychopharmacology",
issn = "0269-8811",
publisher = "SAGE Publications Ltd",
number = "2",
}